Title of article
Ambrisentan-induced severe asymptomatic thrombocytopenia
Author/Authors
Kigitovica, Dana Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Šablinskis, Matiss Medical Faculty - Riga Stradins University - Riga - Latvia , Lejniece, Sandra Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Lejnieks, Aivars Department of Internal Diseases - Riga Stradins University - Riga - Latvia , Skride, Andris Department of Internal Diseases - Riga Stradins University - Riga - Latvia
Pages
2
From page
285
To page
286
Abstract
A systematic review has reported that the prevalence of
connective tissue disease (CTD)-associated pulmonary arterial
hypertension (PAH) is estimated to be 13% (1). The latest guidelines recommend monotherapy with ambrisentan for patients
in World Health Organization functional class (WHO-FC) II (2),
which offers a relative lack of drug interactions and safety (3).
Keywords
Pulmonary arterial hypertension , Ambrisentan , Thrombocytopenia
Journal title
The Anatolian Journal of Cardiology: Andolu Kardiyoloji Dergisi
Serial Year
2020
Record number
2565559
Link To Document